Abstract
Mogamulizumab, a humanized monoclonal antibody targeting the CCR4 chemokine receptor, has recently been approved for the treatment of cutaneous epidermotropic T lymphomas. Rash has been reported as one of the side effects. We report six original cases of granulomatous mogamulizumab-associated rash on photo exposed areas clinically mimicking disease progression, which poses a challenge for clinicians.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
